FDA approves ANDA of 20mg generic Nitisinone capsules
Nitisinone capsules are indicated for patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine
Read Moreby Jen Brogan | Jun 1, 2023 | News | 0
Nitisinone capsules are indicated for patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine
Read Moreby John Pinching | Dec 5, 2022 | News | 0
The therapy has reduced inflammation and supported the remodelling of damaged bone
Read Moreby Fleur Jeffries | Oct 31, 2022 | News | 0
A final decision for daprodustat by the FDA is expected by 1 February 2023
Read Moreby Fleur Jeffries | Aug 22, 2022 | News | 0
Epidiolex may ease symptoms associated with Doose syndrome, a rarer type of childhood-onset epilepsy
Read Moreby John Pinching | Aug 18, 2022 | News | 0
Therapy for the treatment of myelofibrosis has received significant results from phase 3 trial
Read Moreby Lucy Parsons | Sep 21, 2021 | News | 0
Cabometyx found to reduce the risk of disease progression or death versus placebo in this patient population
Read Moreby Lucy Parsons | Aug 18, 2021 | News | 0
Indicated for the treatment of of dMMR recurrent or advanced solid tumours
Read Moreby Lucy Parsons | Aug 16, 2021 | News | 0
Recent trial showed improved immune response after third dose
Read Moreby Lucy Parsons | Aug 3, 2021 | News | 0
Tecentriq is first and only cancer immunotherapy with positive Phase III results in adjuvant lung cancer setting
Read Moreby Lucy Parsons | Jul 8, 2021 | News | 0
Priority review comes following positive results from the Phase III NAVIGATOR trial
Read Moreby Lucy Parsons | Jul 2, 2021 | News | 0
Rylaze has been specifically developed for patients who have developed hypersensitivity to E.coli-derived asparaginase
Read Moreby Lucy Parsons | Jun 24, 2021 | News | 0
Designation is based on data from a Phase IIb study including 856 patients with mild Alzheimer’s disease
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479